Skip to main content

Targeting hypoxic prostate tumours using the novel hypoxia-activated prodrug OCT1002 inhibits expression of genes associated with malignant progression.

Nesbitt H, Byrne NM, Williams N, Ming L, Worthington J, Errington RJ, Patterson LH, Smith P, McKeown SR, McKenna DJ

You May Also Be Interested In:

BSC Technical Training | Baker Company | Oct 19-21, 2026

Read more

Read more about BSC Technical Training | <span translate='no'>Baker</span> Company | Oct 19-21, 2026

Baker Flow Werkbanken – Kwaliteit die blijft presteren

Read more

Read more about <span translate='no'>Baker</span> Flow Werkbanken – Kwaliteit die blijft presteren

Baker Hosts International Dealer Meeting & Factory Visit in Bridgend, Wales

Read more

Read more about <span translate='no'>Baker</span> Hosts International Dealer Meeting &amp; Factory Visit in Bridgend, Wales

First EuroFlow EF-N Installed in the U.S. at University of Miami Sylvester Comprehensive Cancer Center

Read more

Read more about First EuroFlow EF-N Installed in the U.S. at University of Miami Sylvester Comprehensive Cancer Center

Cold Lab Services and The Baker Company: A Strong New Partnership

Read more

Read more about Cold Lab Services and The <span translate='no'>Baker</span> Company: A Strong New Partnership

Lifecycle Support Update 2026: Baker and/or CleanAir Benelux Flowbenches

Read more

Read more about Lifecycle Support Update 2026: <span translate='no'>Baker</span> and/or CleanAir Benelux Flowbenches

The Baker Company certified ISO 14001:2015 for 2026

Read more

Read more about The <span translate='no'>Baker</span> Company certified ISO 14001:2015 for 2026

How Hypoxia Rewires Epigenetics and Splicing to Drive EMT in Breast Cancer

Read more

Read more about How Hypoxia Rewires Epigenetics and Splicing to Drive EMT in Breast Cancer

What Oxygen Really Means for Extracellular Vesicles

Read more

Read more about What Oxygen Really Means for Extracellular Vesicles

Stay up to date